喹诺酮类抗菌药不良反应的研究进展

刘倩; 张晶; 林立敏; 卢克鹏; 宋洪涛; 刘倩; 张晶; 林立敏; 卢克鹏; 宋洪涛

doi:10.3969/j.issn.1006-0111.2015.06.007

[1]

Tome AM,Filipe A. Quinolones:review of psychiatric and neurological adverse reactions[J]. Drug Saf,2011,34(6):465-484.

[2]

张霞光,李天云. 喹诺酮类抗菌药在临床使用中的不良反应[J].国外医药(抗生素分册),2003,24:30-33.

[3]

Kim J,Ohtani H,Tsujimoto M. Quantitative comparison of the convulsive activity of ombinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents[J].Drug Metab Pharmacok,2009,24(2):167-174.

[4]

陈翠环,潘宁开. 喹诺酮类药物诱发精神症状的回顾性分析[J].实用医技杂志,2008,15(10):1278-1279.

[5]

操银针. 喹诺酮类药物引起神经系统不良反应358例分析[J].医药导报,2007,26(10):1246-1247.

[6]

Ray WA,Murray KT,Hall,et al. Azithromycin and the risk of cardiovascular death[J].N Engl J Med,2012,366:1881-1890.

[7]

Lapi F,Wilchesky M, Kezouh A,et al. Fluoroquinolones and the risk of serious arrhythmia: a population-based study[J].Clin Infect Dis,2012,55:1457-65.

[8]

Adefurin A,Sammons H,Jacqz-Aigrain E,et al. Ciprofloxacin safety in paediatrics: a systematic review[J].Arch Dis Child,2011,96:874-80.

[9]

Schaad UB. Will fluoroquinolones ever be recommended for common infections in children?[J].Pediatr Infect Dis J,2007,26:865-867.

[10]

Pichichero ME,Arguedas A, Dagan R,et al. Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and/or AOM treatment failure[J].Clin Infect Dis, 2005,41:470-478.

[11]

Seeger JD,West WA,Fife D,et al. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in amanaged care population[J]. Pharmacoepidemiol Drug Safe,2006,15:784-792.

[12]

Wise BL,Peloquin C,Choi H,et al. Impact of age,obesity,and steroiduse on quinolone-associated tendon disorders[J].Am J Med,2012,125:23-28.

[13]

Mandell LA,Ball P,Tillotson G. Antimicrobial safety and toler ability:differences and dilemmas[J].Clin Infect Dis,2001,32(Suppl):72-79.

[14]

Paterson JM,Mamdani MM, Manno M,et al. Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study[J].CMAJ,2012,184:1565-1570.

[15]

Etminan M, Forooghian F,Brophy JM,et al. Oral fluoroquinolones and the risk of retinal detachment[J].JAMA, 201,307:1414-1419.

[16]

Albini TA,Karakousis PC,Abbey AM,et al. Association between oral fluoroquinolones and retinal detachment[J].Am J Ophthalmol, 2012,154:919-921.

[17]

Christ W, Lehnert T,Ulbrich B. Specific toxicologic aspects of the quinolones[J].Rev Infect Dis,1988,10:141-146.

[18]

Kato M,Onodera T. Morphological investigation of cavity formation in articular cartilage induced by ofloxacin in rats[J].Fundam Appl Toxicol,1988,11 (1):110-119.

[19]

Grady R. Safety profile of quinolone antibiotics in the pediatric population[J].Pediatr Infect Dis,2003,22 (12):1128-1132.

[20]

van der Linden PD, Sturkenboom MC, Herings RM,et al. Fluoroquinolones and risk of achilles tendon disorders:case-control study[J].BMJ,2002, 324(7349):1306-1307.

[21]

Shaughnessy MK,Amundson WH, Kuskowski MA,et al. Unnecessary antimicrobial use in patients with current or recent Clostridium difficile infection[J].Infect Control Hosp Epidemiol,2013,34:109-116.